Plus Therapeutics, Inc.
PSTVNASDAQHealthcare● Active
$5.53
+$0.12(+2.22%)
Market Cap$13380410
P/E Ratio—
52W High$23.5
52W Low$2.9
Plus Therapeutics, Inc. (PSTV) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · PSTV · as of 2026-06-08
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $5.21M | $5.82M | $4.91M | $0.22M | $0.00M |
| Cost of Revenue | $0.45M | $0.85M | $9.69M | $0.71M | $0.07M |
| Gross Profit | $4.77M | $4.97M | ($4.78M) | ($0.49M) | ($0.07M) |
| Gross Margin %(computed) | 91.46% | 85.37% | -97.23% | -217.86% | — |
| Operating Expenses | |||||
| R&D Expenses | $8.38M | $10.58M | $9.69M | $9.70M | $5.32M |
| G&A Expenses | $12.13M | $9.94M | $8.54M | $0.00M | $6.85M |
| Total Operating Expenses | $20.07M | $19.67M | $8.54M | $19.22M | $12.43M |
| Operating Income | ($15.30M) | ($14.70M) | ($13.32M) | ($19.71M) | ($12.49M) |
| Operating Margin %(computed) | -293.46% | -252.32% | -271.14% | — | — |
| Interest Income | $0.12M | $0.27M | $0.40M | $0.15M | $0.02M |
| Interest Expense | $3.61M | $3.72M | $0.40M | $0.71M | $0.93M |
| Income Before Tax | ($22.39M) | ($12.98M) | ($13.32M) | ($20.27M) | ($13.40M) |
| Income Tax Expense | $0.00M | $0.00M | $0.00M | $0.00M | $0.00M |
| Net Income | ($22.39M) | ($12.98M) | ($13.32M) | ($20.27M) | ($13.40M) |
| Net Margin %(computed) | -429.43% | -222.84% | -271.04% | — | — |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-7.19 | $-48.75 | $-106000.00 | $-288750.00 | $-444500.00 |
| Wtd Avg Shares | 3.11M | 0.27M | 0.00M | 0.00M | 0.00M |
| EBITDA | ($14.85M) | ($8.40M) | ($12.69M) | ($18.85M) | ($12.05M) |
| EBITDA Margin %(computed) | -284.92% | -144.27% | -258.36% | — | — |
Data source: Financial Modeling Prep · Last updated: 2026-06-08 · USD · M
Explore more Plus Therapeutics, Inc. data
About Plus Therapeutics, Inc. (PSTV) Income Statement
Plus Therapeutics, Inc. (PSTV) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2025, PSTV reported revenue of $0.01B, gross profit of $0.00B (gross margin 91.46%), and net income of ($0.02B) — a net profit margin of -429.43%.
Frequently asked questions
PSTV · 4 questionsPlus Therapeutics, Inc. (PSTV) reported revenue of $0.01B for 2025, down 10.5% year-over-year.
PSTV revenuePSTV salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-08